1.53 USD
-0.04 (-2.55%)
1.52 USD
-0.01 (-0.65%)
We assign a fundamental rating of 2 out of 10 to BNGO. BNGO was compared to 57 industry peers in the Life Sciences Tools & Services industry. BNGO has a bad profitability rating. Also its financial health evaluation is rather negative. BNGO is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
BNGO had negative earnings in the past year.
In the past year BNGO has reported a negative cash flow from operations.
In the past 5 years BNGO always reported negative net income.
BNGO had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -97.79%, BNGO is not doing good in the industry: 91.23% of the companies in the same industry are doing better.
The Return On Equity of BNGO (-163.82%) is worse than 80.70% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -97.79% | ||
| ROE | -163.82% | ||
| ROIC | N/A |
ROA(3y)-99.22%
ROA(5y)-76.96%
ROE(3y)-203.87%
ROE(5y)-150.04%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 5.05%, BNGO is doing worse than 89.47% of the companies in the same industry.
In the last couple of years the Gross Margin of BNGO has declined.
The Profit Margin and Operating Margin are not available for BNGO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 5.05% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-61.43%
GM growth 5Y-48.22%
2. Health
2.1 Basic Checks
BNGO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BNGO has less shares outstanding
The number of shares outstanding for BNGO has been reduced compared to 5 years ago.
The debt/assets ratio for BNGO is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -14.19, we must say that BNGO is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -14.19, BNGO is not doing good in the industry: 91.23% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.08 indicates that BNGO is not too dependend on debt financing.
BNGO's Debt to Equity ratio of 0.08 is in line compared to the rest of the industry. BNGO outperforms 59.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.08 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -14.19 |
ROIC/WACCN/A
WACC53.14%
2.3 Liquidity
A Current Ratio of 1.76 indicates that BNGO should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.76, BNGO is doing worse than 66.67% of the companies in the same industry.
A Quick Ratio of 1.41 indicates that BNGO should not have too much problems paying its short term obligations.
BNGO has a Quick ratio of 1.41. This is in the lower half of the industry: BNGO underperforms 64.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.76 | ||
| Quick Ratio | 1.41 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 77.75% over the past year.
Looking at the last year, BNGO shows a very negative growth in Revenue. The Revenue has decreased by -14.79% in the last year.
The Revenue has been growing by 24.89% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)77.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.38%
Revenue 1Y (TTM)-14.79%
Revenue growth 3Y19.62%
Revenue growth 5Y24.89%
Sales Q2Q%-9.75%
3.2 Future
BNGO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.92% yearly.
Based on estimates for the next years, BNGO will show a very strong growth in Revenue. The Revenue will grow by 22.69% on average per year.
EPS Next Y92.3%
EPS Next 2Y39.87%
EPS Next 3Y25.68%
EPS Next 5Y14.92%
Revenue Next Year-2.24%
Revenue Next 2Y10.35%
Revenue Next 3Y21.7%
Revenue Next 5Y22.69%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
BNGO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BNGO. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
BNGO's earnings are expected to grow with 25.68% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.87%
EPS Next 3Y25.68%
5. Dividend
5.1 Amount
No dividends for BNGO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
1.53
-0.04 (-2.55%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners8.78%
Inst Owner Change93.03%
Ins Owners3.19%
Ins Owner Change0%
Market Cap15.58M
Revenue(TTM)30.78M
Net Income(TTM)-74.33M
Analysts80
Price Target7.65 (400%)
Short Float %11.75%
Short Ratio3.15
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)40.95%
Min EPS beat(2)19.21%
Max EPS beat(2)62.68%
EPS beat(4)2
Avg EPS beat(4)-40.88%
Min EPS beat(4)-158.66%
Max EPS beat(4)62.68%
EPS beat(8)5
Avg EPS beat(8)-4.99%
EPS beat(12)6
Avg EPS beat(12)-6.18%
EPS beat(16)6
Avg EPS beat(16)-11.58%
Revenue beat(2)1
Avg Revenue beat(2)-0.91%
Min Revenue beat(2)-3.37%
Max Revenue beat(2)1.56%
Revenue beat(4)3
Avg Revenue beat(4)7.29%
Min Revenue beat(4)-3.37%
Max Revenue beat(4)29.08%
Revenue beat(8)5
Avg Revenue beat(8)3.18%
Revenue beat(12)8
Avg Revenue beat(12)2.63%
Revenue beat(16)11
Avg Revenue beat(16)3.31%
PT rev (1m)-21.05%
PT rev (3m)-21.05%
EPS NQ rev (1m)0%
EPS NQ rev (3m)7.95%
EPS NY rev (1m)-3.33%
EPS NY rev (3m)13.31%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0.08%
Revenue NY rev (3m)0.08%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.57 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.34 | ||
| P/tB | 0.41 | ||
| EV/EBITDA | N/A |
EPS(TTM)-20.56
EYN/A
EPS(NY)-3.64
Fwd EYN/A
FCF(TTM)-2.56
FCFYN/A
OCF(TTM)-2.56
OCFYN/A
SpS2.69
BVpS4.46
TBVpS3.77
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -97.79% | ||
| ROE | -163.82% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 5.05% | ||
| FCFM | N/A |
ROA(3y)-99.22%
ROA(5y)-76.96%
ROE(3y)-203.87%
ROE(5y)-150.04%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-61.43%
GM growth 5Y-48.22%
F-Score4
Asset Turnover0.36
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.08 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 0% | ||
| Cap/Sales | 0% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.76 | ||
| Quick Ratio | 1.41 | ||
| Altman-Z | -14.19 |
F-Score4
WACC53.14%
ROIC/WACCN/A
Cap/Depr(3y)12.46%
Cap/Depr(5y)12.34%
Cap/Sales(3y)4.56%
Cap/Sales(5y)3.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)77.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.38%
EPS Next Y92.3%
EPS Next 2Y39.87%
EPS Next 3Y25.68%
EPS Next 5Y14.92%
Revenue 1Y (TTM)-14.79%
Revenue growth 3Y19.62%
Revenue growth 5Y24.89%
Sales Q2Q%-9.75%
Revenue Next Year-2.24%
Revenue Next 2Y10.35%
Revenue Next 3Y21.7%
Revenue Next 5Y22.69%
EBIT growth 1Y50.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year82.38%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y80.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y80.42%
OCF growth 3YN/A
OCF growth 5YN/A
BIONANO GENOMICS INC / BNGO FAQ
What is the fundamental rating for BNGO stock?
ChartMill assigns a fundamental rating of 2 / 10 to BNGO.
What is the valuation status for BNGO stock?
ChartMill assigns a valuation rating of 1 / 10 to BIONANO GENOMICS INC (BNGO). This can be considered as Overvalued.
Can you provide the profitability details for BIONANO GENOMICS INC?
BIONANO GENOMICS INC (BNGO) has a profitability rating of 0 / 10.